US House Republicans Launch Oversight Of Medicare Price ‘Negotiation’ Program
Executive Summary
Offering a glimpse of what to expect if the GOP wins the House in the midterm elections, Reps. McMorris Rodgers and Brady urge transparency from HHS, ask lots of questions, and request monthly briefings on plans for implementation.
You may also be interested in...
As US House Changes Hands, CMS May Face More Oversight Than FDA
Key Republican committee chairs on health issues are familiar faces, largely supportive of the US FDA’s approach to drug regulation. Implementation of the new pricing law, however, will get a lot more scrutiny.
Republican Leaders In Congress Want To Undercut Drug Pricing Law: What’s The Opportunity?
As Republicans expand their power in Congress, experts weigh in on prospects for significant changes to the Medicare price negotiation law and what the GOP might do to hamper implementation of the program.
US Price Negotiation Process: Is Case-By-Case Politically Sustainable?
Republican Congressional letter asking HHS nuts-and-bolts questions about the newly enacted drug price ‘negotiation’ law points to a much more fundamental issue: can a bureaucratic agency make the program work in a manner that appears credible and free of undue political interference?